CagriSema
Also known as: cagrisema
CagriSema is Novo Nordisk's investigational once-weekly fixed-dose co-formulation of cagrilintide 2.4 mg (long-acting amylin analog) with semaglutide 2.4 mg (GLP-1 receptor agonist) for chronic weight management. Unlike the other grey-market blends, it has a proper Phase 3 clinical program. Novo Nordisk filed an FDA NDA in December 2025; as of April 2026 it is under FDA review and not yet approved.
0 listings, ranked by trust score
Each row is a (vendor, peptide) pair. Click through for the listing detail, the vendor's full trust profile, and any COAs they've published.
No vendors carrying this peptide are indexed yet.
COAs for CagriSema
5 third-party tests across 3 vendors. Each card links to the full report.
For
CagriSema
by Simple Peptide· batch 02-21101-02905-P
For
CagriSema
by Simple Peptide· batch CGSM09032025-J
For
CagriSema
by Profound Aminos· batch 2025-04-31
For
CagriSema
by Hydro Research Peptides· batch 2024-08-05
For
CagriSema
by Profound Aminos· batch cmojb7ss001e3kirxyi4q8sbq